“CureDuchenne is a leader in funding pioneering research aimed at advancing the best possible therapies for DMD patients, and we value their vote of confidence and financial support of our snRNA-mediated exon skipping platform,” said Jim Burns, Ph.D., Locanabio’s chief executive officer.
Newport Beach, Calif. (May 11, 2023) – CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD). […]
CureDuchenne Ventures announces an investment in Insmed Inc. to support the development of INS1201, their next generation intracerebroventricular (ICV) delivered AAV to directly address limitations of current gene therapy approaches.
CureDuchenne’s Second Annual “Napa in Miami” Wine Tasting and Auction Raises More Than $1.2 Million to Help Find a Cure for Duchenne Muscular Dystrophy
CureDuchenne and PicnicHealth Announce Real-World Evidence-Focused Partnership to Incorporate Participant Medical Records into CureDuchenne Link
CureDuchenne’s Second Annual “Napa in Miami” Wine Tasting and Auction Raises More Than $1.2 Million to Help Find a Cure for Duchenne Muscular Dystrophy
First CureDuchenne Clinic Opens in Greater Dallas to Provide Specialized Care for Underserved Duchenne Muscular Dystrophy Patients
CureDuchenne Ventures Invests in hC Bioscience and its Novel tRNA-Based Therapeutic Approach for Duchenne Muscular Dystrophy
Savvy Business Veteran Ryan T. Meardon Bolsters Executive Team, Bringing High-Level Strategic Planning and Leadership to Global Rare Disease Nonprofit Newport Beach, Calif. – February 1, 2023 – CureDuchenne, a global […]